Literature DB >> 10492853

Future directions in thrombolysis.

J T Willerson1, P Zoldhelyi.   

Abstract

An extensive body of research conducted in the past 25 years has helped foster understanding of the mechanisms and pathogenesis of the acute coronary syndromes and occlusive disease. Thus, it is well established that thrombosis is caused by vascular injury and that immediate lysis of the arterial thrombus and subsequent prevention of thrombotic reocclusion are critical to the treatment of these disorders. Remarkable progress in the understanding of the biological and molecular mechanisms involved in vascular-wall-platelet interactions, platelet-platelet interactions, and coagulation has led to the identification of multiple targets for drug discovery and the development of numerous antithrombotic drugs. The purpose of this article is to review emerging antithrombotic therapies, introduce potential future molecular targets for drug discovery efforts, and discuss novel strategies for managing patients with coronary disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492853      PMCID: PMC6655810          DOI: 10.1002/clc.4960221608

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  79 in total

Review 1.  Molecular and cellular biology of blood coagulation.

Authors:  B Furie; B C Furie
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

2.  Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.

Authors:  D C Mills; R Puri; C J Hu; C Minniti; G Grana; M D Freedman; R F Colman; R W Colman
Journal:  Arterioscler Thromb       Date:  1992-04

Review 3.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

Authors:  V Fuster; L Badimon; J J Badimon; J H Chesebro
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

4.  ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.

Authors:  S K Yao; J C Ober; J McNatt; C R Benedict; M Rosolowsky; H V Anderson; K Cui; J P Maffrand; W B Campbell; L M Buja
Journal:  Circ Res       Date:  1992-01       Impact factor: 17.367

5.  Ticlopidine and platelet function in healthy volunteers.

Authors:  A Dembinska-Kiec; I Virgolini; F Rauscha; H Sinzinger
Journal:  Thromb Res       Date:  1992-03-01       Impact factor: 3.944

6.  Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets.

Authors:  T Palabrica; R Lobb; B C Furie; M Aronovitz; C Benjamin; Y M Hsu; S A Sajer; B Furie
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

Review 7.  Why do plaques rupture?

Authors:  E Falk
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

Review 8.  Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.

Authors:  J H Chesebro; M W Webster; P Zoldhelyi; P C Roche; L Badimon; J J Badimon
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

Review 9.  Hirudins: antithrombin anticoagulants.

Authors:  K A Stringer; J Lindenfeld
Journal:  Ann Pharmacother       Date:  1992-12       Impact factor: 3.154

Review 10.  Development of GPIIb/IIIa antagonists as antithrombotic drugs.

Authors:  A J Nichols; R R Ruffolo; W F Huffman; G Poste; J Samanen
Journal:  Trends Pharmacol Sci       Date:  1992-11       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.